A Vaccine for Alzheimer’s Disease? An Interview With AC Immune’s Prof Andrea Pfeifer

 

Swiss biopharma AC Immune has made targeting Alzheimer’s disease, the leading form of dementia, a top priority. The company’s numerous candidates and platforms target several different proteins and pathways thought to have a central role in Alzheimer’s pathology. 2020 has brought mixed news for AC Immune. In July, the company announced that their candidate tau vaccine, ACI-35.030, had shown “encouraging” safety data at a lower dose and was to be progressed to a higher-dose group. However, September brought the disappointing news that their anti-tau antibody, semorinemab, did not meet its primary efficacy endpoints in a Phase 2 trial. To discuss AC Immune’s work, Technology Networks spoke to CEO Prof. Andrea Pfeifer.

Read the full story ... >>

 


The views and opinions expressed in the article are solely those of their authors, and do not necessarily reflect the opinions and beliefs of AmericanScience.org.


About Us

American Science (AmericanScience.org) is dedicated to advancing scientific knowledge and professional growth. We deliver the latest news, research updates, and valuable career resources across all areas of science. Our mission is to connect scientists, researchers, and others to foster an informed and vibrant scientific community. More ... >>

Contact info

AmericanScience.org
9951 ATLANTIC BLVD., STE 105
JACKSONVILLE, FL 32225
U.S.A.
Email: staff@americanscience.org
Phone: (904) 638-1058

Career Network

www.postdocjobs.comwww.stemcareers.com